Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Maurizio Fava, M.D.

Co-Author

This page shows the publications co-authored by Maurizio Fava and Marlene Freeman.
Connection Strength

7.881
  1. Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, Sanacora G, Iosifescu DV, DeBattista C, Trivedi MH, Fava M. Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
    View in: PubMed
    Score: 0.973
  2. Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, Mathew S, Sanacora G, Iosifescu D, DeBattista C, Trivedi MH, Fava M. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019 03; 110:166-171.
    View in: PubMed
    Score: 0.889
  3. Freeman MP, Pooley J, Flynn MJ, Baer L, Mischoulon D, Mou D, Fava M. Guarding the Gate: Remote Structured Assessments to Enhance Enrollment Precision in Depression Trials. J Clin Psychopharmacol. 2017 Apr; 37(2):176-181.
    View in: PubMed
    Score: 0.786
  4. Freeman MP, Fisher L, Clain A, Rabbitt R, Pooley J, Baer L, Fava M. Differentiating residual symptoms of depression from adverse events among patients initiating treatment with an antidepressant. Ann Clin Psychiatry. 2017 02; 29(1):28-34.
    View in: PubMed
    Score: 0.777
  5. Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016 10; 21(10):1372-80.
    View in: PubMed
    Score: 0.718
  6. Freeman MP, Walker R, Laughren TP, Miller KK, Fava M. Female reproductive life cycle and hormones: methodology to improve clinical trials. J Clin Psychiatry. 2013 Oct; 74(10):1018-21.
    View in: PubMed
    Score: 0.617
  7. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1604.
    View in: PubMed
    Score: 0.246
  8. Freeman MP, Fava M, Dirks B, Jha MK, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S. Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. Depress Anxiety. 2020 May; 37(5):485-495.
    View in: PubMed
    Score: 0.243
  9. Freeman MP, Fava M, Dirks B, Jha MK, Shelton RC, Thase ME, Trivedi MH, Papakostas GI, Liu K, Whitworth T, Stankovic S. 180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin. CNS Spectr. 2020 Apr; 25(2):313-314.
    View in: PubMed
    Score: 0.242
  10. Fava M, Dirks B, Freeman MP, Shelton RC, Thase ME, Trivedi MH, Papakostas GI, Liu K, Whitworth T, Stankovic S. 181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder. CNS Spectr. 2020 Apr; 25(2):314-315.
    View in: PubMed
    Score: 0.242
  11. Fava M, Dirks B, Freeman MP, Papakostas GI, Shelton RC, Thase ME, Trivedi MH, Liu K, Stankovic S. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). J Clin Psychiatry. 2019 09 24; 80(6).
    View in: PubMed
    Score: 0.233
  12. Kinrys G, Gold AK, Pisano VD, Freeman MP, Papakostas GI, Mischoulon D, Nierenberg AA, Fava M. Tachyphylaxis in major depressive disorder: A review of the current state of research. J Affect Disord. 2019 02 15; 245:488-497.
    View in: PubMed
    Score: 0.219
  13. Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
    View in: PubMed
    Score: 0.218
  14. Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI. Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). Brain Stimul. 2018 Jan - Feb; 11(1):75-84.
    View in: PubMed
    Score: 0.203
  15. Mischoulon D, Zajecka J, Freeman MP, Fava M. Does folic acid interfere with lamotrigine? Lancet Psychiatry. 2016 08; 3(8):704-705.
    View in: PubMed
    Score: 0.188
  16. Freeman MP, Fava M, Gommoll C, Chen C, Greenberg WM, Ruth A. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder. Int Clin Psychopharmacol. 2016 Mar; 31(2):100-9.
    View in: PubMed
    Score: 0.182
  17. Fisher LB, Fava M, Doros GD, Alpert JE, Henry M, Huz I, Freeman MP. The Role of Anger/Hostility in Treatment-Resistant Depression: A Secondary Analysis From the ADAPT-A Study. J Nerv Ment Dis. 2015 Oct; 203(10):762-8.
    View in: PubMed
    Score: 0.177
  18. Goldberg JF, Freeman MP, Balon R, Citrome L, Thase ME, Kane JM, Fava M. THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS' PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS. Depress Anxiety. 2015 Aug; 32(8):605-13.
    View in: PubMed
    Score: 0.174
  19. Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry. 2010 Jun; 71(6):669-81.
    View in: PubMed
    Score: 0.122
  20. Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010 Jun; 71(6):682-8.
    View in: PubMed
    Score: 0.122
  21. Shelton RC, Fava M, Freeman MP, Thase ME, Papakostas GI, Jha MK, Trivedi MH, Dirks B, Liu K, Stankovic S. Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. J Affect Disord. 2020 Aug 26; 277:478-485.
    View in: PubMed
    Score: 0.062
  22. Papakostas GI, Fava M, Freeman MP, Shelton RC, Thase ME, Jha MK, Trivedi MH, Dirks B, Liu K, Stankovic S. Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. Int Clin Psychopharmacol. 2020 Aug 13.
    View in: PubMed
    Score: 0.062
  23. Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. J Affect Disord. 2020 01 01; 260:131-139.
    View in: PubMed
    Score: 0.058
  24. Salloum NC, Fava M, Freeman MP, Flynn M, Hoeppner B, Hock RS, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
    View in: PubMed
    Score: 0.055
  25. Desseilles M, Witte J, Chang TE, Iovieno N, Dording C, Ashih H, Nyer M, Freeman MP, Fava M, Mischoulon D. Massachusetts General Hospital SAFER criteria for clinical trials and research. Harv Rev Psychiatry. 2013 Sep-Oct; 21(5):269-74.
    View in: PubMed
    Score: 0.038
  26. Desseilles M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Nyer M, Freeman MP, Fava M, Mischoulon D. Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire. J Clin Psychiatry. 2011 Aug; 72(8):1152-4.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.